In a research paper published in the Journal of Parenteral and Enteral Nutrition, researchers from the University of Leicester Trust Healthcare Affiliated Hospital say that adding omega-3 fatty acid classes to anti-tumor drugs may help improve cancer patients’ response to therapy and their quality of life. The researchers studied 50 patients with malignant pancreatic cancer who were given 1,000 mg of gemcitabine per week, followed by up to 100 g of omega-3-rich fatty milk for three weeks, followed by one week of rest; the treatment continued for six cycles, during which time there was patient progression, unacceptable toxicity, patient requests and death. This study is the first to use omega-3 fatty acids in combination with cancer chemotherapy agents to examine the effects of combination therapy on cancer patients. The results showed a significant improvement in the quality of life of the patients studied, as well as a corresponding decrease in drug reactivity, disease stabilization and liver metastasis. The investigators found the results of this paper very encouraging and will conduct a randomized phase 3 clinical trial for more in-depth studies and investigations.